Antihistamine treatment for allergic rhinitis: different routes, different outcomes?
Allergic rhinitis is one of the most common chronic disorders in the United States, causing patients significant discomfort and interfering with quality of life and functioning. Histamine is the primary mediator in the development of allergic rhinitis symptoms and is a primary therapeutic target. Guidelines, both in the United States and globally, recommend antihistamines as first-line therapy of allergic rhinitis. This article discusses the outcomes associated with intranasal versus oral administration of antihistamines. Both oral and intranasal antihistamines are approved for the first-line treatment of allergic rhinitis and both formulations result in a reduction in symptoms and an improvement in quality of life. Intranasal agents may be preferred in patients in whom nasal congestion is particularly bothersome or in cases where a more rapid onset of action is desired. Oral agents would be a better choice in young children (especially children who are at risk of developing asthma), in cases of poor medication compliance, and in patients who are bothered most by histamine-associated symptoms, such as itching or red and watery eyes. Both oral and intranasal antihistamines are safe and well tolerated and meet the needs of patients with allergic rhinitis, especially those with mild to moderate disease.
Chipps
Bradley E
BE
Capital Allergy and Respiratory Disease Center, Sacramento, California, USA. bchipps@capitalallergy.com
Harder
Julia M
JM
D000281:Administration, Intranasal; D000284:Administration, Oral; D017281:Cost of Illness; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors*; D017410:Practice Guidelines as Topic; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014481:United States
D006633:Histamine Antagonists; D018836:Inflammation Mediators